AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28765326
Drug: Azacitidine (AZA)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine (AZA) combined with Vorinostat (VOR) (300 mg twice a day on days 3 to 9)
Trial: 21507715
Drug: Subcutaneous bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous bortezomib (1.3 mg/m2, twice per week)
Trial: 21507715
Drug: Intravenous bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous bortezomib (1.3 mg/m2, twice per week)
Trial: 11993078
Drug: Intercostal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal nerve blockade (ICB) with ropivacaine 1% (4 times 5 ml)
Trial: 11993078
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with 7.5 mg piritramid i.v. before extubation and continuing with 2 mg boli and a 10 min lockout
Trial: 8553906
Drug: High-dose IL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IL-2 (18 million IU/day subcutaneously for 3 days)
Trial: 8553906
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2 (6 million IU/day subcutaneously for 5 days) plus MLT (40 mg/day orally)
Trial: 7058754
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 30 mg
Trial: 7058754
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 60 mg
Trial: 7058754
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 15 mg (four times daily)
Trial: 7058754
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 30 mg (four times daily)
Trial: 7058754
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (various doses)
Trial: 30669825
Drug: Schroth therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schroth therapy
Trial: 29125382
Drug: Intra-sheath injection
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-sheath injection of 1ml of 40mg/ml methyl prednisolone acetate
Trial: 29125382
Drug: Extra-sheath injection
RxNorm normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-sheath injection of 1ml of 40mg/ml methyl prednisolone acetate
Trial: 25984794
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) after 8 sessions
Trial: 22480620
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX‐A) injections into plantar flexor muscles
Trial: 11804663
Drug: Ethanol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (40 g/day) for 4 weeks
Trial: 7487127
Drug: Azasetron (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azasetron (10 mg/day)
Trial: 2148146
Drug: Low-oestrogen combined
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-oestrogen combined pill
Trial: 28166190
Drug: Whole Stribild
RxNorm normalized name: Stribild
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Whole Stribild tablet with breakfast (reference)
Trial: 23547240
Drug: Nebivolol (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5-20 mg/d)
Trial: 23547240
Drug: Metoprolol (100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100-300 mg/d)
Trial: 21486442
Drug: Higher Relative
RxNorm normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher Relative Total Dose Intensity (RTDI)
Trial: 19222455
Drug: 5-ALA patch-PDT
RxNorm normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-ALA patch-PDT
Trial: 7967349
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker (nifedipine) pretreatment
Trial: 3302010
Drug: Sucralfate, 1g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate, 1g twice daily
Trial: 23527868
Drug: Moderately intoxicating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately intoxicating dose of alcohol (mean blood alcohol concentration = 0.076 g/dl)
Trial: 18977646
Drug: Beclomethasone dipropionate/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate/formoterol combination via single inhaler
Trial: 18977646
Drug: Beclomethasone dipropionate/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate/formoterol combination via separate inhalers
Trial: 13678928
Drug: Insulin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (10 IU)
Trial: 11003253
Drug: Human ultralente
RxNorm normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human ultralente insulin injected at 17.00 h
Trial: 11003253
Drug: Human ultralente
RxNorm normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human ultralente insulin injected at 22.00 h
Trial: 11003253
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin injected before dinner
Trial: 11003253
Drug: Human ultralente
RxNorm normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human ultralente insulin (in general)
Trial: 6418897
Drug: Intravesical chemotherapy
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical chemotherapy (thiotepa or VM26)
Trial: 30888448
Drug: Conventional technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional technique with ST/G autograft
Trial: 25822598
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (techniques chosen by surgeons)
Trial: 25822598
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment (initial sling immobilization followed by active rehabilitation)
Trial: 24023786
Drug: simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg and ezetimibe 10 mg combination
Trial: 19002384
Drug: Vandetanib 100
RxNorm normalized name: vandetanib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 100 mg plus mFOLFOX6
Trial: 19002384
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg plus mFOLFOX6
Trial: 17255230
Drug: Allopurinol (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (900 mg/d)
Trial: 15599989
Drug: Moderately active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately active topical corticosteroids
Trial: 11740820
Drug: Neovastat in
RxNorm normalized name: Neovastat
DrugBank: Neovastat (DB05387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neovastat in addition to induction chemotherapy/radiotherapy
Trial: 11740820
Drug: Neovastat as
RxNorm normalized name: Neovastat
DrugBank: Neovastat (DB05387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neovastat as a monotherapy
Trial: 7620239
Drug: Adrenaline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline (5 mg)
Trial: 2836651
Drug: hCRF (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCRF (2 micrograms/kg body weight) with naloxone (1.6 mg i.v. bolus, followed by an infusion at a rate of 1.2 mg/h)
Trial: 29847831
Drug: Antidepressant pharmacotherapy
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant pharmacotherapy
Trial: 29847831
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CBASP + pharmacotherapy)
Trial: 29847831
Drug: Monotherapy (either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (either CBASP or pharmacotherapy)
Trial: 16549259
Drug: Headache Impact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Headache Impact Test (HIT) administered at baseline and 6-week follow-up
Trial: 14596323
Drug: Mg citrate
RxNorm normalized name: K-Mg Citrate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg citrate
Trial: 14596323
Drug: Mg amino-acid
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg amino-acid chelate
Trial: 14596323
Drug: Mg oxide
RxNorm normalized name: citric acid/Mg oxide/Na picosulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg oxide
Trial: 9715552
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily gentamicin regimen (4 mg/kg Q 24 h)
Trial: 9715552
Drug: Conventional gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional gentamicin regimen (2.5 mg/kg Q 12 h)
Trial: 8285548
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.25% bupivacaine
Trial: 8285548
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of saline
Trial: 27367263
Drug: Treatment 'failures'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 'failures' (heavy drinkers) in COMBINE
Trial: 27367263
Drug: Treatment 'failures'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 'failures' (heavy drinkers) in Project MATCH
Trial: 27367263
Drug: Treatment 'successes'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 'successes' (non-heavy drinkers)
Trial: 26042037
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg cocoa supplementation (acute)
Trial: 26042037
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg cocoa supplementation (sub-chronic)
Trial: 23816723
Drug: Fosinopril (5-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (5-40 mg/day)
Trial: 23816723
Drug: Dioscorea bulbifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dioscorea bulbifera (500 mg BD)
Trial: 18720882
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone combined with conventional methods
Trial: 18720882
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone injection combined with conventional methods
Trial: 18720882
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone injection via external ear combined with conventional methods
Trial: 18720882
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone injection via pharyngotympanic tube combined with conventional methods
Trial: 16051416
Drug: Propranolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (2 mg or 4 mg i.v.) combined with oxytocin
Trial: 11093393
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg three times daily for five days
Trial: 11093393
Drug: Paracetamol 500
RxNorm normalized name: Paracetamol 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 500 mg with codeine 30 mg six hourly for 5 days
Trial: 3957487
Drug: Deriphyllin-Digoxin tablets
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deriphyllin-Digoxin tablets
Trial: 15661109
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg bodyweight)
Trial: 10232640
Drug: Transgalactooligosaccharides 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transgalactooligosaccharides 15 g/d
Trial: 10232640
Drug: Transgalactooligosaccharides 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transgalactooligosaccharides 7.5 g/d
Trial: 30507211
Drug: Culturally accommodated
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally accommodated treatment (A-CBT)
Trial: 30507211
Drug: Standard group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group-based cognitive-behavioral treatment (S-CBT)
Trial: 24008122
Drug: Aliskiren/amlodipine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren/amlodipine combination therapy (150mg aliskiren + 5mg amlodipine for 8 weeks, then 300mg aliskiren + 5mg amlodipine for another 8 weeks)
Trial: 24008122
Drug: High-dose amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose amlodipine monotherapy (10mg amlodipine for 16 weeks)
Trial: 20036363
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day (early intensive lipid-lowering therapy)
Trial: 11845337
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (soft cervical collar)
Trial: 10430396
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy (Pantoprazole 40 mg daily, Amoxycilline 1000 mg b.i.d., Clarithromycine 500 mg b.i.d.)
Trial: 6110818
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine given one month after hepatitis B immune globulin injection
Trial: 6110818
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine and immune globulin given simultaneously
Trial: 6110818
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine given alone
Trial: 24289099
Drug: Internet-based guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based guided self-help treatment
Trial: 18753119
Drug: Interviewer-administered questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-administered questionnaire (IAQ)
Trial: 17402320
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy targeting glucose at 110‐140 mg/dl
Trial: 17402320
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin therapy controlling glucose at 140‐200 mg/dl when exceeding 200 mg/dl
Trial: 11210405
Drug: Fluoxetine 60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 60 mg daily for 8 days + Almotriptan 12.5 mg on Day 8
Trial: 11210405
Drug: Almotriptan 12.5
RxNorm normalized name: almotriptan 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan 12.5 mg on Day 8
Trial: 10194994
Drug: Paracetamol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (20 mg/kg)
Trial: 31738228
Drug: Nortriptyline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline + Morphine combination therapy
Trial: 26879587
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (20 IU twice daily)
Trial: 26162657
Drug: Short-term therapies
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term therapies (SPP and SFT)
Trial: 23451806
Drug: Once-daily prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily prolonged-release mesalazine (4 g/day)
Trial: 23451806
Drug: Twice-daily prolonged-release
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily prolonged-release mesalazine (4 g/day)
Trial: 18405442
Drug: Targeted agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted agents targeting the hypoxia inducible factor-alfa (HIF-) / vascular endothelial growth factor (VEGF) pathway and mammalian target of rapamycin (mTOR) signal transduction pathway
Trial: 15273470
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 0.05 mg/kg/day for 1 year
Trial: 2965154
Drug: rIFN alpha
RxNorm normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN alpha 2C (2MU) given subcutaneously 5 times per week for 8-12 weeks, then once weekly until week 48.
Trial: 2965154
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of rIFN alpha 2C (2MU) and medroxyprogesterone acetate (MPA) 750 mg p.o. daily until week 48.
Trial: 2965154
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group not explicitly mentioned, but both treatment groups had a median survival of 7 months.
Trial: 26477350
Drug: MRI-specific play
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-specific play therapy intervention
Trial: 24594090
Drug: i-gel supraglottic
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel supraglottic airway (IG-SGA)
Trial: 22744207
Drug: Outpatient long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Outpatient long-term treatment
Trial: 20412877
Drug: Intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination (0.2 ml, 6 microg HA per strain, split into two-site injections)
Trial: 20412877
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination (0.5 ml, 15 microg HA per strain)
Trial: 12235694
Drug: 12 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months after cessation of chemotherapy
Trial: 10421395
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition plus chemotherapy
Trial: 2160490
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (15 capsules of 1 g fish oil daily)
Trial: 2160490
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil control (15 capsules of 1 g olive oil daily)
Trial: 433814
Drug: Pure ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pure ethanol (9.3% w/v aqueous solution)
Trial: 19860612
Drug: Weekly methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly methotrexate (MTX) and daily 6-mercaptopurine maintenance therapy
Trial: 18092436
Drug: Intranasal Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal Midazolam 0.2 mg/kg
Trial: 18092436
Drug: Intranasal Ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Ketamine 5 mg/kg
Trial: 7857503
Drug: Hypericum extract
RxNorm normalized name: Hypericum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum extract (3 x 300 mg)
Trial: 7857503
Drug: Maprotiline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (3 x 25 mg)
Trial: 870015
Drug: Intracameral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral injection of 50 microng of gentamicin
Trial: 870015
Drug: Systemic and
RxNorm normalized name: Estradiol and Levonorgestrel Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic and topical chloramphenicol prophylaxis (historical control)
Trial: 31856835
Drug: Doorstep provision
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doorstep provision of oral contraceptive pills and condoms